TY - JOUR
T1 - Risk for anemia in pediatric chronic kidney disease patients
T2 - A report of NAPRTCS
AU - Atkinson, Meredith A.
AU - Martz, Karen
AU - Warady, Bradley A.
AU - Neu, Alicia M.
N1 - Funding Information:
Dr. Atkinson was supported by grant funding from Amgen, The Thrasher Research Fund, The National Kidney Foundation of Maryland, and The National Kidney Foundation.
PY - 2010/9
Y1 - 2010/9
N2 - Previous studies in children with chronic kidney disease (CKD) have identified low hemoglobin as a risk factor for poor outcomes. A retrospective review of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) CKD registry was performed to identify the prevalence of and risk factors for anemia among children with stage 3 CKD, including both patients with low hemoglobin and those whose hemoglobin normalized with an erythropoiesis-stimulating agent (ESA). At enrollment, 2,792 patients had stage 3 CKD. Mean age was 9.5 (±0.11) years, 62.1% were male, 61.3% were white, and 43.7% had structural/urologic disease. Among 1,640 of those patients with 12 month follow-up data available for multivariate analysis, 73% met the criteria for anemia. Multivariate logistic regression analysis identifying risk factors for anemia at the 12-month follow-up revealed that, after controlling for estimated glomerular filtration rate, age >2 years, male sex, earlier era of study entry, and prescription of anti-hypertensive medications are associated with an increased risk for anemia at 12 months. In addition, multivariate Cox proportional hazards regression analysis revealed that when patients with ESA-corrected hemoglobin are included in the definition, anemia is not associated with increased risk of progression to end stage renal disease (dialysis initiation or transplantation).
AB - Previous studies in children with chronic kidney disease (CKD) have identified low hemoglobin as a risk factor for poor outcomes. A retrospective review of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) CKD registry was performed to identify the prevalence of and risk factors for anemia among children with stage 3 CKD, including both patients with low hemoglobin and those whose hemoglobin normalized with an erythropoiesis-stimulating agent (ESA). At enrollment, 2,792 patients had stage 3 CKD. Mean age was 9.5 (±0.11) years, 62.1% were male, 61.3% were white, and 43.7% had structural/urologic disease. Among 1,640 of those patients with 12 month follow-up data available for multivariate analysis, 73% met the criteria for anemia. Multivariate logistic regression analysis identifying risk factors for anemia at the 12-month follow-up revealed that, after controlling for estimated glomerular filtration rate, age >2 years, male sex, earlier era of study entry, and prescription of anti-hypertensive medications are associated with an increased risk for anemia at 12 months. In addition, multivariate Cox proportional hazards regression analysis revealed that when patients with ESA-corrected hemoglobin are included in the definition, anemia is not associated with increased risk of progression to end stage renal disease (dialysis initiation or transplantation).
KW - Anti-hypertensives
KW - CKD stage
KW - Erythropoietin stimulating agent
KW - Progression
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=77955013503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955013503&partnerID=8YFLogxK
U2 - 10.1007/s00467-010-1538-6
DO - 10.1007/s00467-010-1538-6
M3 - Article
C2 - 20464428
AN - SCOPUS:77955013503
SN - 0931-041X
VL - 25
SP - 1699
EP - 1706
JO - Pediatric Nephrology
JF - Pediatric Nephrology
IS - 9
ER -